Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, that focuses on developing therapeutic products aimed at treating and preventing serious infectious diseases. The company is working on several key therapies, including VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for human immunodeficiency virus, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established collaborations and agreements with various organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, Brii Biosciences, Alnylam Pharmaceuticals, and others, to further its research and development efforts. Additionally, it has a manufacturing agreement with Samsung Biologics for producing antibodies related to COVID-19 treatments. Founded in 2016, Vir Biotechnology aims to leverage its innovative platforms to potentially eradicate diseases like hepatitis B, influenza A, HIV, and tuberculosis.
Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at tackling diseases linked to latent or persistent viral reservoirs. The company employs advanced nucleases, including CRISPR/Cas9 technology, to precisely target and disrupt viral DNA. Established in 2014 and headquartered in South San Francisco, California, Agenovir operates as a subsidiary of Vir Biotechnology, Inc. Its innovative approach seeks to create a new class of nuclease-based antiviral therapeutics that can effectively eliminate pathogenic viral genomes, thereby providing healthcare providers with tools to treat patients suffering from severe and persistent viral infections.
Humabs BioMed SA, founded in 2004 and based in Bellinzona, Switzerland, specializes in developing human monoclonal antibody platforms aimed at treating infectious and inflammatory diseases. The company focuses on generating innovative therapies through partnerships with pharmaceutical firms and universities. Currently, Humabs has two clinical-stage programs: one in collaboration with MedImmune, a subsidiary of AstraZeneca, which involves an antibody targeting the influenza A virus that has shown efficacy against various subtypes, and another partnered with Novartis, which is in phase 2 development for an undisclosed target. Humabs' antibody technologies are designed to elicit therapeutic immune responses to combat serious infections, addressing gaps in treatment for both common and rare diseases.
TomegaVax Inc. is an immunotherapy company that applies a game-changing vaccine technology platform to areas of unmet medical need. The company is focused on the preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Hepatitis B Virus (HBV) and Herpes Simplex Virus (HSV).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.